BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33721353)

  • 1. Treatment approach, hospital practice patterns, and receipt of multimodality therapy as measures of quality for locally advanced gastric cancer.
    Portuondo JI; Tran Cao HS; da Costa WL; Sada YH; Harris AHS; Massarweh NN
    J Surg Oncol; 2021 May; 123(8):1724-1735. PubMed ID: 33721353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer.
    Sada YH; Smaglo BG; Tran Cao HS; Mok H; Musher BL; Massarweh NN
    J Surg Res; 2019 May; 237():41-49. PubMed ID: 30694790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer.
    Li SS; Udelsman BV; Parikh A; Klempner SJ; Clark JW; Roeland EJ; Wo JY; Hong TS; Mullen JT
    J Am Coll Surg; 2020 Jun; 230(6):912-924. PubMed ID: 32035978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival.
    Lowenfeld L; Datta J; Lewis RS; McMillan MT; Mamtani R; Damjanov N; Chandrasekhara V; Karakousis GC; Drebin JA; Fraker DL; Roses RE
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S863-72. PubMed ID: 26100818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoption of evidence-based novel therapies in the treatment of gastric cancer: A national observational study.
    Mokdad AA; Ali A; Yopp AC; Polanco PM; Nassour I; Mansour JC; Choti MA; Minter RM; Wang SC; Porembka MR
    Cancer; 2018 Mar; 124(6):1122-1131. PubMed ID: 29211302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit.
    Schouwenburg MG; Busweiler LAD; Beck N; Henneman D; Amodio S; van Berge Henegouwen MI; Cats A; van Hillegersberg R; van Sandick JW; Wijnhoven BPL; Wouters MWJ; Nieuwenhuijzen GAP;
    Eur J Surg Oncol; 2018 Apr; 44(4):532-538. PubMed ID: 29439836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: Evidence from the American College of Surgeons National Cancer Database.
    Greenleaf EK; Hollenbeak CS; Wong J
    Surgery; 2016 Apr; 159(4):1099-112. PubMed ID: 26704785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study.
    Mokadem I; Dijksterhuis WPM; van Putten M; Heuthorst L; de Vos-Geelen JM; Haj Mohammad N; Nieuwenhuijzen GAP; van Laarhoven HWM; Verhoeven RHA
    Gastric Cancer; 2019 Nov; 22(6):1263-1273. PubMed ID: 30949777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do hospital attributes predict guideline-recommended gastric cancer care in the United States?
    Dudeja V; Gay G; Habermann EB; Tuttle TM; Tseng JF; Feig BW; Al-Refaie WB
    Ann Surg Oncol; 2012 Feb; 19(2):365-72. PubMed ID: 21837530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors contributing to variation in the use of multimodality treatment in patients with gastric cancer: A Dutch population based study.
    Beck N; Busweiler LAD; Schouwenburg MG; Fiocco M; Cats A; Voncken FEM; Wijnhoven BPL; van Berge Henegouwen MI; Wouters MWJM; van Sandick JW;
    Eur J Surg Oncol; 2018 Feb; 44(2):260-267. PubMed ID: 29273212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma.
    Sada YH; Smaglo BG; Tan JC; Tran Cao HS; Musher BL; Massarweh NN
    J Natl Compr Canc Netw; 2019 Feb; 17(2):161-168. PubMed ID: 30787129
    [No Abstract]   [Full Text] [Related]  

  • 12. Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States.
    Datta J; McMillan MT; Ruffolo L; Lowenfeld L; Mamtani R; Plastaras JP; Dempsey DT; Karakousis GC; Drebin JA; Fraker DL; Roses RE
    Ann Surg Oncol; 2016 Sep; 23(9):2936-45. PubMed ID: 27090793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in the use of evidence-based therapy for resectable gastric cancer.
    Snyder RA; Penson DF; Ni S; Koyama T; Merchant NB
    J Surg Oncol; 2014 Sep; 110(3):285-90. PubMed ID: 24891231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States.
    Sherman KL; Merkow RP; Bilimoria KY; Wang CE; Mulcahy MF; Benson AB; Bentrem DJ
    Ann Surg Oncol; 2013 Feb; 20(2):362-70. PubMed ID: 22890592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer.
    Dimou F; Sineshaw H; Parmar AD; Tamirisa NP; Jemal A; Riall TS
    J Gastrointest Surg; 2016 Jan; 20(1):93-103; discussion 103. PubMed ID: 26503262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial.
    Shen J; Cao B; Wang Y; Xiao A; Qin J; Wu J; Yan Q; Hu Y; Yang C; Cao Z; Hu J; Yin P; Xie D; Gong J
    Trials; 2018 Aug; 19(1):432. PubMed ID: 30092843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in gastric cancer care: a trend beyond racial disparities.
    Al-Refaie WB; Gay G; Virnig BA; Tseng JF; Stewart A; Vickers SM; Tuttle TM; Feig BW
    Cancer; 2010 Jan; 116(2):465-75. PubMed ID: 19950130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery.
    Coimbra FJF; de Jesus VHF; Ribeiro HSC; Diniz AL; de Godoy AL; de Farias IC; Felismino T; Mello CAL; Almeida MF; Begnami MDFS; Dias-Neto E; Riechelmann RSP; da Costa WL
    Ann Surg Oncol; 2019 Oct; 26(11):3618-3626. PubMed ID: 31222685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative.
    Jin LX; Sanford DE; Squires MH; Moses LE; Yan Y; Poultsides GA; Votanopoulos KI; Weber SM; Bloomston M; Pawlik TM; Hawkins WG; Linehan DC; Schmidt C; Worhunsky DJ; Acher AW; Cardona K; Cho CS; Kooby DA; Levine EA; Winslow E; Saunders N; Spolverato G; Colditz GA; Maithel SK; Fields RC
    Ann Surg Oncol; 2016 Aug; 23(8):2398-408. PubMed ID: 27006126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer.
    Li SS; Klempner SJ; Costantino CL; Parikh A; Clark JW; Wo JY; Hong TS; Mullen JT
    Ann Surg Oncol; 2021 May; 28(5):2856-2865. PubMed ID: 33393043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.